Description
Available Combinations & Strengths:
- ALENZA-L
Montelukast 10 mg + Levocetirizine 5 mg Film-Coated Tablet - ALENZA-FX
Montelukast 10 mg + Fexofenadine 120 mg Film-Coated Tablet - ALENZA-B
Bilastine 20 mg + Montelukast Sodium 10 mg Film-Coated Tablet
ALENZA-L TABLETS
Introduction:
Alenza-L is a fixed-dose combination of Bilastine and Montelukast Sodium, formulated for effective and well-tolerated treatment of allergic conditions.
- Bilastine is a next-generation, non-sedating, highly selective H1 receptor antagonist from the piperidine class, structurally distinct from other antihistamines.
- Montelukast is a leukotriene receptor antagonist that synergizes with Bilastine to enhance anti-allergic and anti-inflammatory action.
- This combination offers additive therapeutic benefits as demonstrated in both in vitro and in vivo
Composition:
Each film-coated tablet contains:
- Bilastine – 20 mg
- Montelukast Sodium – 10 mg
Indications:
- Symptomatic relief of nasal and non-nasal symptoms of seasonal and perennial allergic rhinitis (≥12 years)
- Symptomatic relief in chronic spontaneous urticaria (≥18 years)
Mechanism of Action:
- Bilastine: Blocks H1 receptors to reduce symptoms such as sneezing, itching, rhinorrhea, and swelling.
- Montelukast: Blocks CysLT1 receptors, preventing bronchoconstriction and inflammation, thus improving airflow and reducing mucus production.
Pharmacokinetics of Bilastine:
- Oral bioavailability: ~61%
- Cmax: 220 ng/mL (≈1.3 hours post-dose)
- Half-life: ~14.5 hours
- Plasma protein binding: 84–90%
- Excretion: ~95% unchanged (67% via feces, 33% via urine)
Dosage & Administration:
- Once daily or as directed by a healthcare professional
- To ensure optimal absorption: take 1 hour before or 2 hours after food or fruit juice
Presentation:
- 1×10 strip pack
Reviews
There are no reviews yet.